Is SNTI or MREO more profitable?

Mereo BioPharma Group's return on equity of -74.82% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Senti Biosciences N/A -1,629.80% -119.72% Mereo BioPharma Group N/A -74.82% -64.28%

Do analysts recommend RNAZ or SNTI?

Senti Biosciences has a consensus target price of $10.00, suggesting a potential upside of 2,570.23%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Senti Biosciences is more favorable than TransCode Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Is RNAZ or SNTI more profitable?

TransCode Therapeutics' return on equity of -875.35% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TransCode Therapeutics N/A -875.35% -37.46% Senti Biosciences N/A -1,629.80% -119.72%

Is TVGN or SNTI more profitable?

Tevogen Bio's return on equity of 0.00% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -468.32% Senti Biosciences N/A -1,629.80% -119.72%

Senti Biosciences (SNTI) Competitors

$0.37 0.00 (-0.66%)

As of 03:12 PM Eastern

Compare

SNTI vs. MCRB, MREO, MGX, RNAZ, and TVGN

Should you buy Senti Biosciences stock or one of its competitors? Senti Biosciences's main competitors and comparable companies include Seres Therapeutics (MCRB), Mereo BioPharma Group (MREO), Metagenomi (MGX), TransCode Therapeutics (RNAZ), and Tevogen Bio (TVGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Senti Biosciences compare to Seres Therapeutics?

Senti Biosciences (NASDAQ:SNTI) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

Senti Biosciences has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Seres Therapeutics' return on equity of -114.82% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-1,629.80%	-119.72%
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%

Senti Biosciences currently has a consensus target price of $10.00, indicating a potential upside of 2,570.23%. Seres Therapeutics has a consensus target price of $17.00, indicating a potential upside of 243.43%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Senti Biosciences is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Seres Therapeutics had 1 more articles in the media than Senti Biosciences. MarketBeat recorded 2 mentions for Seres Therapeutics and 1 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 1.89 beat Seres Therapeutics' score of 0.93 indicating that Senti Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Senti Biosciences	Very Positive
Seres Therapeutics	Positive

Seres Therapeutics has higher revenue and earnings than Senti Biosciences. Seres Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$55K	212.07	-$61.44M	-$1.77	N/A
Seres Therapeutics	$790K	62.97	$5.70M	-$2.43	N/A

Senti Biosciences has a beta of 2.1, suggesting that its share price is 110% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Summary

Senti Biosciences beats Seres Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Senti Biosciences compare to Mereo BioPharma Group?

Senti Biosciences (NASDAQ:SNTI) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Senti Biosciences has a beta of 2.1, meaning that its stock price is 110% more volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

In the previous week, Senti Biosciences and Senti Biosciences both had 1 articles in the media. Senti Biosciences' average media sentiment score of 1.89 beat Mereo BioPharma Group's score of 1.87 indicating that Senti Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Senti Biosciences	Very Positive
Mereo BioPharma Group	Very Positive

Senti Biosciences currently has a consensus price target of $10.00, suggesting a potential upside of 2,570.23%. Mereo BioPharma Group has a consensus price target of $1.67, suggesting a potential upside of 505.84%. Given Senti Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Senti Biosciences is more favorable than Mereo BioPharma Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Mereo BioPharma Group's return on equity of -74.82% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-1,629.80%	-119.72%
Mereo BioPharma Group	N/A	-74.82%	-64.28%

Mereo BioPharma Group has higher revenue and earnings than Senti Biosciences. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$55K	212.07	-$61.44M	-$1.77	N/A
Mereo BioPharma Group	$500K	87.86	-$41.88M	-$0.04	N/A

Summary

Mereo BioPharma Group beats Senti Biosciences on 8 of the 15 factors compared between the two stocks.

How does Senti Biosciences compare to Metagenomi?

Senti Biosciences (NASDAQ:SNTI) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

Senti Biosciences has a beta of 2.1, meaning that its stock price is 110% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

25.7% of Senti Biosciences shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by company insiders. Comparatively, 12.5% of Metagenomi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Senti Biosciences has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -63.65% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-1,629.80%	-119.72%
Metagenomi	-384.61%	-63.65%	-44.52%

Senti Biosciences has higher earnings, but lower revenue than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$55K	212.07	-$61.44M	-$1.77	N/A
Metagenomi	$25.21M	1.77	-$87.87M	-$2.49	N/A

In the previous week, Metagenomi had 2 more articles in the media than Senti Biosciences. MarketBeat recorded 3 mentions for Metagenomi and 1 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 1.89 beat Metagenomi's score of 0.62 indicating that Senti Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Senti Biosciences	Very Positive
Metagenomi	Positive

Senti Biosciences presently has a consensus price target of $10.00, suggesting a potential upside of 2,570.23%. Metagenomi has a consensus price target of $6.00, suggesting a potential upside of 408.47%. Given Senti Biosciences' higher possible upside, equities analysts clearly believe Senti Biosciences is more favorable than Metagenomi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Senti Biosciences beats Metagenomi on 9 of the 14 factors compared between the two stocks.

How does Senti Biosciences compare to TransCode Therapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and Senti Biosciences (NASDAQ:SNTI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, TransCode Therapeutics had 1 more articles in the media than Senti Biosciences. MarketBeat recorded 2 mentions for TransCode Therapeutics and 1 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 1.89 beat TransCode Therapeutics' score of 0.94 indicating that Senti Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
TransCode Therapeutics	Positive
Senti Biosciences	Very Positive

TransCode Therapeutics has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.1, suggesting that its stock price is 110% more volatile than the broader market.

TransCode Therapeutics' return on equity of -875.35% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-37.46%
Senti Biosciences	N/A	-1,629.80%	-119.72%

TransCode Therapeutics has higher earnings, but lower revenue than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$52.37	N/A
Senti Biosciences	$55K	212.07	-$61.44M	-$1.77	N/A

25.7% of Senti Biosciences shares are owned by institutional investors. 0.1% of TransCode Therapeutics shares are owned by insiders. Comparatively, 3.1% of Senti Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Senti Biosciences has a consensus target price of $10.00, suggesting a potential upside of 2,570.23%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Senti Biosciences is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Senti Biosciences beats TransCode Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Senti Biosciences compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and Senti Biosciences (NASDAQ:SNTI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

25.7% of Senti Biosciences shares are owned by institutional investors. 65.6% of Tevogen Bio shares are owned by company insiders. Comparatively, 3.1% of Senti Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Tevogen Bio presently has a consensus price target of $100.00, indicating a potential upside of 1,355.60%. Senti Biosciences has a consensus price target of $10.00, indicating a potential upside of 2,570.23%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Senti Biosciences is more favorable than Tevogen Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Tevogen Bio has a beta of 0.18, indicating that its stock price is 82% less volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.1, indicating that its stock price is 110% more volatile than the broader market.

Tevogen Bio's return on equity of 0.00% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-468.32%
Senti Biosciences	N/A	-1,629.80%	-119.72%

In the previous week, Tevogen Bio and Tevogen Bio both had 1 articles in the media. Senti Biosciences' average media sentiment score of 1.89 beat Tevogen Bio's score of 1.87 indicating that Senti Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Tevogen Bio	Very Positive
Senti Biosciences	Very Positive

Tevogen Bio has higher earnings, but lower revenue than Senti Biosciences. Tevogen Bio is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A
Senti Biosciences	$55K	212.07	-$61.44M	-$1.77	N/A

Summary

Senti Biosciences beats Tevogen Bio on 11 of the 14 factors compared between the two stocks.

Get Senti Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SNTI vs. The Competition

Export

Metric	Senti Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.66M	$3.91B	$7.11B	$12.80B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	-0.21	11.79	272.84	25.46
Price / Sales	212.07	1,392.91	685.44	122.44
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	2.08	16.73	11.01	6.31
Net Income	-$61.44M	-$22.71M	$3.47B	$349.45M
7 Day Performance	-0.93%	2.32%	1.03%	-0.23%
1 Month Performance	9.99%	12.44%	8.03%	4.24%
1 Year Performance	-74.52%	53.96%	23.84%	14.60%

Senti Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SNTI Senti Biosciences	3.2094 of 5 stars	$0.37 -0.7%	$10.00 +2,570.2%	-74.4%	$11.66M	$55K	N/A	4	Positive News Gap Down
MCRB Seres Therapeutics	2.6384 of 5 stars	$5.00 +7.3%	$17.00 +240.0%	-73.0%	$46.81M	$790K	N/A	330
MREO Mereo BioPharma Group	3.2098 of 5 stars	$0.28 -2.7%	$1.67 +491.9%	-85.2%	$46.23M	$500K	N/A	40	Positive News
MGX Metagenomi	3.2118 of 5 stars	$1.21 flat	$6.00 +395.9%	-31.6%	$45.71M	$25.21M	N/A	236
RNAZ TransCode Therapeutics	0.9765 of 5 stars	$2.53 -6.3%	N/A	-77.6%	$45.71M	N/A	N/A	9	News Coverage Positive News Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SNTI) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Senti Biosciences (SNTI) Competitors

SNTI vs. MCRB, MREO, MGX, RNAZ, and TVGN

How does Senti Biosciences compare to Seres Therapeutics?

Summary

How does Senti Biosciences compare to Mereo BioPharma Group?

Summary

How does Senti Biosciences compare to Metagenomi?

Summary

How does Senti Biosciences compare to TransCode Therapeutics?

Summary

How does Senti Biosciences compare to Tevogen Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI vs. The Competition

Senti Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Senti Biosciences (SNTI) Competitors

SNTI vs. MCRB, MREO, MGX, RNAZ, and TVGN

How does Senti Biosciences compare to Seres Therapeutics?

Is SNTI or MCRB more profitable?

Do analysts prefer SNTI or MCRB?

Do institutionals and insiders believe in SNTI or MCRB?

Does the media prefer SNTI or MCRB?

Which has stronger earnings & valuation, SNTI or MCRB?

Which has more volatility & risk, SNTI or MCRB?

Summary

How does Senti Biosciences compare to Mereo BioPharma Group?

Which has more volatility & risk, SNTI or MREO?

Does the media prefer SNTI or MREO?

Do analysts rate SNTI or MREO?

Do institutionals & insiders believe in SNTI or MREO?

Is SNTI or MREO more profitable?

Which has stronger valuation and earnings, SNTI or MREO?

Summary

How does Senti Biosciences compare to Metagenomi?

Which has more risk and volatility, SNTI or MGX?

Do insiders & institutionals believe in SNTI or MGX?

Is SNTI or MGX more profitable?

Which has higher earnings & valuation, SNTI or MGX?

Does the media prefer SNTI or MGX?

Do analysts recommend SNTI or MGX?

Summary

How does Senti Biosciences compare to TransCode Therapeutics?

Does the media refer more to RNAZ or SNTI?

Which has more risk & volatility, RNAZ or SNTI?

Is RNAZ or SNTI more profitable?

Which has better earnings & valuation, RNAZ or SNTI?

Do insiders and institutionals hold more shares of RNAZ or SNTI?

Do analysts recommend RNAZ or SNTI?

Summary

How does Senti Biosciences compare to Tevogen Bio?

Do insiders & institutionals have more ownership in TVGN or SNTI?

Do analysts recommend TVGN or SNTI?

Which has more risk and volatility, TVGN or SNTI?

Is TVGN or SNTI more profitable?

Does the media prefer TVGN or SNTI?

Which has stronger valuation & earnings, TVGN or SNTI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI vs. The Competition

Senti Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools